The European Commission (EC) has granted marketing authorization for Sandoz’s Wyost (denosumab) and Jubbonti (denosumab), the first and only biosimilar versions of reference medicines Xgeva and Prolia in Europe.   Wyost is approved for the treatment of cancer-related bone disease, while Jubbonti is approved to treat osteoporosis. These are key biosimilar value drivers for the company over the mid-term and their approval is a major step in advancing the Sandoz growth strategy. The biosimilars a...